F
Frontier Biotechnologies Inc
SSE:688221
Frontier Biotechnologies Inc
SSE:688221
Price:
20.51
CNY
-0.58%
Market Closed
Market Cap:
¥7.7B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
F
|
Frontier Biotechnologies Inc
SSE:688221
|
CN |
Income Statement
Earnings Waterfall
Frontier Biotechnologies Inc
Frontier Biotechnologies Inc
Income Statement
Frontier Biotechnologies Inc
Frontier Biotechnologies Inc
Currency: CNY
| Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||||
| Interest Expense |
4
|
4
|
3
|
5
|
5
|
6
|
7
|
8
|
9
|
10
|
10
|
10
|
11
|
0
|
0
|
|
| Revenue |
40
N/A
|
44
+9%
|
64
+45%
|
85
+33%
|
91
+7%
|
101
+11%
|
99
-2%
|
114
+15%
|
127
+11%
|
123
-3%
|
134
+9%
|
129
-3%
|
133
+3%
|
137
+3%
|
141
+3%
|
|
| Gross Profit | ||||||||||||||||
| Cost of Revenue |
(54)
|
(54)
|
(68)
|
(69)
|
(77)
|
(82)
|
(78)
|
(81)
|
(89)
|
(84)
|
(89)
|
(96)
|
(92)
|
(94)
|
(95)
|
|
| Gross Profit |
(13)
N/A
|
(10)
+27%
|
(5)
+53%
|
15
N/A
|
14
-9%
|
19
+33%
|
21
+14%
|
33
+55%
|
38
+15%
|
39
+2%
|
45
+15%
|
34
-25%
|
41
+21%
|
43
+4%
|
46
+8%
|
|
| Operating Income | ||||||||||||||||
| Operating Expenses |
(307)
|
(316)
|
(340)
|
(394)
|
(404)
|
(442)
|
(405)
|
(365)
|
(354)
|
(361)
|
(327)
|
(251)
|
(304)
|
(252)
|
(280)
|
|
| Selling, General & Administrative |
(141)
|
(141)
|
(138)
|
(135)
|
(142)
|
(148)
|
(145)
|
(157)
|
(159)
|
(155)
|
(151)
|
(165)
|
(176)
|
(172)
|
(182)
|
|
| Research & Development |
(181)
|
(197)
|
(226)
|
(255)
|
(283)
|
(305)
|
(273)
|
(198)
|
(204)
|
(175)
|
(162)
|
(131)
|
(120)
|
(112)
|
(112)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
(25)
|
0
|
0
|
0
|
(22)
|
0
|
0
|
0
|
(17)
|
0
|
0
|
0
|
|
| Other Operating Expenses |
16
|
22
|
24
|
20
|
21
|
11
|
12
|
12
|
9
|
(31)
|
(14)
|
62
|
(8)
|
33
|
14
|
|
| Operating Income |
(320)
N/A
|
(326)
-2%
|
(344)
-6%
|
(379)
-10%
|
(390)
-3%
|
(423)
-9%
|
(384)
+9%
|
(332)
+14%
|
(316)
+5%
|
(322)
-2%
|
(282)
+12%
|
(217)
+23%
|
(263)
-21%
|
(209)
+20%
|
(234)
-12%
|
|
| Pre-Tax Income | ||||||||||||||||
| Interest Income Expense |
40
|
32
|
29
|
22
|
16
|
16
|
13
|
10
|
11
|
9
|
5
|
6
|
73
|
71
|
67
|
|
| Non-Reccuring Items |
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
(6)
|
(3)
|
(3)
|
(3)
|
10
|
0
|
0
|
(0)
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
(0)
|
0
|
0
|
0
|
|
| Total Other Income |
2
|
3
|
6
|
1
|
1
|
1
|
(2)
|
(1)
|
(1)
|
(1)
|
(0)
|
(0)
|
(0)
|
(0)
|
(0)
|
|
| Pre-Tax Income |
(278)
N/A
|
(291)
-5%
|
(309)
-6%
|
(357)
-15%
|
(373)
-5%
|
(407)
-9%
|
(373)
+8%
|
(329)
+12%
|
(309)
+6%
|
(316)
-2%
|
(280)
+12%
|
(201)
+28%
|
(190)
+6%
|
(138)
+27%
|
(168)
-21%
|
|
| Net Income | ||||||||||||||||
| Tax Provision |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Income from Continuing Operations |
(278)
|
(291)
|
(309)
|
(357)
|
(373)
|
(407)
|
(373)
|
(329)
|
(309)
|
(316)
|
(280)
|
(201)
|
(190)
|
(138)
|
(168)
|
|
| Net Income (Common) |
(274)
N/A
|
(290)
-6%
|
(309)
-7%
|
(357)
-15%
|
(373)
-5%
|
(407)
-9%
|
(373)
+8%
|
(329)
+12%
|
(309)
+6%
|
(316)
-2%
|
(280)
+12%
|
(201)
+28%
|
(190)
+6%
|
(138)
+27%
|
(168)
-21%
|
|
| EPS (Diluted) |
-0.76
N/A
|
-0.81
-7%
|
-0.76
+6%
|
-0.98
-29%
|
-0.99
-1%
|
-1.08
-9%
|
-0.99
+8%
|
-0.88
+11%
|
-0.82
+7%
|
-0.84
-2%
|
-0.75
+11%
|
-0.54
+28%
|
-0.51
+6%
|
-0.37
+27%
|
-0.45
-22%
|
|
Switch to:
Switch to:
See Also
Discover More
